Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$2.8 million.

  • Northwest Biotherapeutics' Net Cash Flow fell 18869.51% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $513000.0, marking a year-over-year increase of 36636.36%. This contributed to the annual value of -$1.2 million for FY2024, which is 7113.07% up from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Net Cash Flow is -$2.8 million, which was down 18869.51% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Net Cash Flow registered a high of $10.9 million during Q4 2021, and its lowest value of -$9.1 million during Q1 2022.
  • Its 5-year average for Net Cash Flow is -$559105.3, with a median of -$560000.0 in 2024.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Net Cash Flow surged by 266203.7% in 2023, and later tumbled by 570000.0% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Net Cash Flow stood at $10.9 million in 2021, then crashed by 96.85% to $342000.0 in 2022, then crashed by 965.79% to -$3.0 million in 2023, then tumbled by 45.8% to -$4.3 million in 2024, then soared by 34.03% to -$2.8 million in 2025.
  • Its Net Cash Flow was -$2.8 million in Q3 2025, compared to $5.5 million in Q2 2025 and $2.2 million in Q1 2025.